The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback